SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose Reduced Stake in Organovo Holdings Below 5%

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting their beneficial ownership in Organovo Holdings, Inc. has decreased to 4.99% of the common stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively beneficially own 102,539 shares of Organovo Holdings, Inc. common stock.
• This represents 4.99% of the company's common stock, indicating a reduction in their stake below the 5% threshold.
• The reporting persons have shared voting power and shared dispositive power over all 102,539 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• This filing is an Amendment No. 2, updating a previously reported beneficial ownership position.
• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends and proceeds from the sale of these securities.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as the filing indicates a reduction in beneficial ownership below the 5% threshold by an institutional investor, which can be perceived as a lack of conviction or a divestment.

Negatives

• The beneficial ownership of Armistice Capital, LLC and Steven Boyd in Organovo Holdings, Inc. has decreased to 4.99%, indicating a reduction in their stake below the 5% threshold.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by Armistice Capital as a negative signal, potentially leading to decreased investor confidence or selling pressure.

Key Dates

Keywords

Organovo Holdings, Armistice Capital, Steven Boyd, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Institutional Investor